Preparation of anti-HER2 monoclonal antibody-paclitaxel immunoconjugate and its biological evaluation

J Huazhong Univ Sci Technolog Med Sci. 2011 Dec;31(6):735-740. doi: 10.1007/s11596-011-0669-8. Epub 2011 Dec 16.

Abstract

Anti-HER2 monoclonal antibody (Sc7301)-paclitaxel (TAX) immunoconjugate was prepared and its specific binding to tumor cells was investigated in this study. Sc7301 was conjugated to TAX by the active ester method and then the TAX-Sc7301 immunoconjugate was obtained. After purification and labeling by Cyano-fluorescein isothiocyanate (FITC), the specific binding of TAX-Sc7301 to HER2-positive tumor cells (SKOV3) and HER2-negative tumor cells (HepG2) was evaluated respectively. TAX-Sc7301 (20 nmol/L) showed distinct specific binding to SKOV3 cells rather than HepG2 cells. And the uptake of the immunoconjugate by SKOV3 cells was increased with the TAX-Sc7301 concentration (3-48 nmol/L) and the incubation time (P<0.05). It was concluded that the TAX-Sc7301 immunoconjugate is potentially applicable as a targeted agent against HER2-positive tumor cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal / biosynthesis*
  • Antibodies, Neoplasm / immunology
  • Cell Line, Tumor
  • Drug Delivery Systems / methods
  • Female
  • Humans
  • Immunoconjugates / pharmacology*
  • Ovarian Neoplasms / metabolism*
  • Ovarian Neoplasms / pathology
  • Paclitaxel* / administration & dosage
  • Paclitaxel* / chemistry
  • Paclitaxel* / pharmacology
  • Receptor, ErbB-2* / antagonists & inhibitors
  • Receptor, ErbB-2* / immunology

Substances

  • Antibodies, Monoclonal
  • Antibodies, Neoplasm
  • Immunoconjugates
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Paclitaxel